Services

Listings
  • Auristatin F

    Auristatin F

    Drug Development Shirley (New York) January 22, 2018 1.00 Dollar US$

    ADCs cytotoxin, Auristatin F is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAF analog and cytotoxin in Antibody-drug conjugates. https://www.creative-biolabs.com/adc/classify-adc-toxins-6.htm

  • Anti-cKIT (NEG024)-SMCC-DM1 ADC

    Anti-cKIT (NEG024)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-cKIT monoclonal antibody (NEG024) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ...

  • Calicheamicin

    Calicheamicin

    Drug Development Shirley (New York) January 22, 2018 1.00 Dollar US$

    ADCs cytotoxin, Calicheamicin is a potent DNA-binding cytotoxic antibiotic. https://www.creative-biolabs.com/adc/classify-adc-toxins-6.htm

  • Anti-cKIT (20376)-SMCC-DM1 ADC

    Anti-cKIT (20376)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-cKIT monoclonal antibody (20376) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the c...

  • Campathecin

    Campathecin

    Drug Development Shirley (New York) January 22, 2018 1.00 Dollar US$

    ADCs cytotoxin, Camptothecin (CPT) is a potent DNA enzyme topoisomerase I (topo I) inhibitor with an IC50 and IC70 of 50 nM and 0.225 μM for breast cancer cell line MDA-MB-231. https://www.creative-biolabs.com/adc/classify-adc-toxins-6.htm

  • Anti-cKIT (NEG086)-SMCC-DM1 ADC

    Anti-cKIT (NEG086)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-cKIT monoclonal antibody (NEG086) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ...

  • D8-MMAE

    D8-MMAE

    Drug Development Shirley (New York) January 22, 2018 1.00 Dollar US$

    ADCs cytotoxin, D8-MMAE(D8-Monomethyl auristatin E; D8-Vedotin) is a deuterated form of MMAE. https://www.creative-biolabs.com/adc/classify-adc-toxins-6.htm

  • Anti-cKIT (NEG087)-SMCC-DM1 ADC

    Anti-cKIT (NEG087)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-cKIT monoclonal antibody (NEG087) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ...

  • Daun02

    Daun02

    Drug Development Shirley (New York) January 22, 2018 1.00 Dollar US$

    ADCs cytotoxin, Daun02 is a daunorubicin b-galactoside prodrug for use in conjunction. https://www.creative-biolabs.com/adc/classify-adc-toxins-6.htm

  • Anti-cKIT (NEG026)-SMCC-DM1 ADC

    Anti-cKIT (NEG026)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-cKIT monoclonal antibody (NEG026) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ...

  • Daunorubicin

    Daunorubicin

    Drug Development Shirley (New York) January 22, 2018 1.00 Dollar US$

    ADCs cytotoxin, Daunorubicin(RP13057) inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM. https://www.creative-biolabs.com/adc/classify-adc-toxins-6.htm

  • Anti-cKIT (NEG027)-SMCC-DM1 ADC

    Anti-cKIT (NEG027)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-cKIT monoclonal antibody (NEG027) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ...